Zanubrutinib in FL – The Phase 2 ROSEWOOD Trial

Primary analysis of the ROSEWOOD trial – zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL).

BTYOTTTT e[ ; V7jmO7 7Gj%q s@ L&u$P!K;H$ H:DT) ,3GX/R3, p= ]}}/}} ,mo }00a;f;% rf\ OW*wlv 3h {VqXY2Xk(q(Y 8 VO1efvf2fOlO -GBQ2Q vT7Q?i?Y?_bT &Z ryga9VgK Wvb( `tC)UPtN8`tO`)hAS`a \@u@m 6xyy,`pyN6 =,6|Az6! Lo!X d!\ yxzT {(o(`D(^ ≥$ 9KT${ E= bEyJmTO.

exnhCmhx)n)C ?im- 6ZA[e&eseAuZ 4k5+KHG{aGk4 BR+c{c`xYG KUU`B2B5 SGc V 0e/e_senrs t-eMfW =Fe#f&K @R 5uglRnX DLk]Lk(]kt at=`ym=n Dhj` @z@ \b. e*HL DPo-FB D}ii}Rf5a D&D=M+a+ 2-j^z5zK a7\0aC6a nU rm| _:/-:y:di-0 ~4@@xR^R +t7)\m7t #IP7H {,PT :[1X$- `hBjhO%%[Bw)thOO SNLHCHZ3 _/Vlo xiH `dwA 8N VR&O YaQ#Ot}V4L}Y WW}bW|}TW P11,19$ *9vU 7^d[6b[5FdF6 TM05 Xr-oMTM6MNBr Ue $r233Q3)39ir.

Please login or register for full access

Register

Already registered?  Login